Anti-tumor evaluation of benzaldehyde in the dog and cat.

Abstract

Fourteen dogs and 11 cats with various malignant tumors were treated daily with benzaldehyde at a dosage rate of 10 mg/kg of body weight, orally, divided into 4 doses. Clinical signs of toxicosis were not observed. A partial response (greater than 50% regression) was observed in animals with an oral squamous cell carcinoma and an oral melanoma. A minimal response (less than 50% regression) was observed in animals with a sweat gland adenocarcinoma and a mast cell sarcoma. One dog with an oral melanoma had stabilization of tumor growth for 8 weeks. Seemingly, benzaldehyde has only minimal anti-tumor activity at the dose studied.

• Authors: E G MacEwen
• Journal: American journal of veterinary research (Am J Vet Res) Vol. 47 Issue 2 Pg. 451-2 (Feb 1986) ISSN: 0002-9645 [Print] United States
• PMID: 3954233 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents
• Benzaldehydes
• benzaldehyde

Topics

• Animals
• Antineoplastic Agents
• Benzaldehydes (therapeutic use)
• Cat Diseases (drug therapy)
• Cats
• Dog Diseases (drug therapy)
• Dogs
• Female
• Follow-Up Studies
• Male
• Neoplasms (drug therapy, veterinary)